Live
CellThe temporal architecture of the seminiferous epithelial cycle revealed by spatial transcriptomicsCellCell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysisCellTransplanting light-dependent reactions for mammalian eye photosynthesisEndpoints NewsMakary resigns; Biogen reports Alzheimer’s data; and more10x Genomics NewsPrecision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders DailyFierceBiotechTransforming neurodegenerative disease treatmentFierceBiotechAdvances and Opportunities in Dual Chamber InjectablesFierceBiotechAchieving Effective Manufacturing Scaleup for Clinical and Commercial SuccessFierceBiotechUtilizing AI to Facilitate Combination Product DevelopmentFierceBiotechEnsuring Sustainability Throughout Drug and Device DevelopmentFierceBiotechUsing Digital Technologies to Enhance Patient Experience and Better Manage Supply ChainEndpoints NewsCDER chief Høeg expected to leave FDA, according to source
Endpoints News Apr 1, 2026

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts

Original
Body unavailable. Use the original source.